报价延迟最少15分钟:2025/08/24 08:39 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.63 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.64/--
|
|
企业价值
10.44M
|
| 资产负债 |
|
每股账面净值
4.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.51M
|
|
每股收益
5.77
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/24 08:39 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asiaregion. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases |
